Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cel...
Saved in:
| Main Authors: | Henrica M J Werner, Jone Trovik, Mari K Halle, Elisabeth Wik, Lars A Akslen, Even Birkeland, Therese Bredholt, Ingvild L Tangen, Camilla Krakstad, Helga B Salvesen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090141&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study.
by: Tormund S Njølstad, et al.
Published: (2017-01-01) -
Stathmin 1 expression in neuroendocrine and proliferating prostate cancer
by: Yingli Shi, et al.
Published: (2025-01-01) -
Multiplex single‐cell profiling of putative cancer stem cell markers ALDH1, SOX9, SOX2, CD44, CD133 and CD15 in endometrial cancer
by: Hilde E. Lien, et al.
Published: (2025-06-01) -
Rac1 and Stathmin but Not EB1 Are Required for Invasion of Breast Cancer Cells in Response to IGF-I
by: Shigeru Morimura, et al.
Published: (2011-01-01) -
Taxanes – The backbone of medical oncology
by: Wesley M Jose
Published: (2020-01-01)